ALTAVILLA, Giuseppe
 Distribuzione geografica
Continente #
NA - Nord America 5.348
EU - Europa 4.839
AS - Asia 949
SA - Sud America 15
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 4
AF - Africa 1
Totale 11.164
Nazione #
US - Stati Uniti d'America 5.339
IE - Irlanda 1.309
SE - Svezia 1.223
CN - Cina 733
IT - Italia 713
UA - Ucraina 463
DE - Germania 295
GB - Regno Unito 236
FI - Finlandia 204
PL - Polonia 156
SG - Singapore 98
IN - India 68
BE - Belgio 63
FR - Francia 61
RU - Federazione Russa 37
VN - Vietnam 18
AT - Austria 16
CZ - Repubblica Ceca 16
ID - Indonesia 13
BR - Brasile 12
ES - Italia 10
NL - Olanda 10
IR - Iran 9
CA - Canada 7
AU - Australia 6
CH - Svizzera 5
TR - Turchia 4
NO - Norvegia 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
CL - Cile 2
EU - Europa 2
GR - Grecia 2
HR - Croazia 2
LV - Lettonia 2
MX - Messico 2
NZ - Nuova Zelanda 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
AM - Armenia 1
BD - Bangladesh 1
CO - Colombia 1
DK - Danimarca 1
EE - Estonia 1
HK - Hong Kong 1
HU - Ungheria 1
IQ - Iraq 1
LT - Lituania 1
MM - Myanmar 1
RS - Serbia 1
SC - Seychelles 1
TH - Thailandia 1
Totale 11.164
Città #
Dublin 1.309
Chandler 1.006
Jacksonville 941
Nyköping 691
Beijing 302
Ashburn 270
Dearborn 251
Ann Arbor 244
Princeton 220
Medford 201
Cambridge 199
Warsaw 156
Des Moines 152
Messina 146
Boardman 129
New York 113
Lancaster 110
Jinan 77
Woodbridge 67
Brussels 60
Shenyang 52
Singapore 51
Wilmington 49
San Mateo 45
Los Angeles 44
Tianjin 39
Nanjing 35
Houston 34
Hyderabad 29
Hebei 27
Catania 26
Pune 26
Zhengzhou 25
Rome 22
Seattle 21
Washington 21
Nanchang 20
Haikou 18
Dong Ket 17
Ningbo 17
Norwalk 17
Vienna 16
Bremen 15
Scarsdale 15
Brno 14
Milan 14
Changsha 13
Hangzhou 13
Jakarta 13
Jiaxing 13
Redwood City 13
Taizhou 13
Helsinki 11
Leawood 11
Saint Petersburg 10
Auburn Hills 8
Guangzhou 8
London 8
Modica 8
Fuzhou 7
Taiyuan 7
Augusta 6
Chicago 6
Clearwater 6
Monmouth Junction 6
Florence 5
Lanzhou 5
Novokuznetsk 5
Vitoria 5
Ardabil 4
Brescia 4
Kemerovo 4
La Spezia 4
Montréal 4
Mumbai 4
Philadelphia 4
Porto Alegre 4
Redmond 4
São Paulo 4
Tappahannock 4
Atlanta 3
Belpasso 3
Caserta 3
Edinburgh 3
Feira de Santana 3
Imola 3
Istanbul 3
Kunming 3
Las Vegas 3
Mili Marina 3
Napoli 3
New Delhi 3
Northampton 3
Padova 3
Phoenix 3
San Giovanni Rotondo 3
Sassari 3
Savona 3
Sona 3
Aci Castello 2
Totale 7.656
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 363
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 126
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 103
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 95
Mechanical dispersion and cardiotoxicity in patients who underwent chemotherapy for breast cancer: an echocardiographic study 94
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 90
Studio anatomo-clinico di due casi di sarcoma sinoviale monofasico del ginocchio 86
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 85
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 81
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 80
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 80
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 80
Razionale e tecniche della chirurgia citoriduttiva e della chemioipertermia peritoneale. 78
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 78
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 78
Increased annual frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. 76
Annual increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily. 76
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 73
Liquid biopsy for lung cancer early detection 73
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 73
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST 72
[Serum levels of copper and zinc in patients with lung cancer] 72
A novel HPLC method for the determination of mitoxantrone in pharmaceutical formulations. 71
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 70
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 70
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 70
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 70
Cancer screening in HIV-infected patients: early diagnosis in a high-risk population 70
Myocardial damage pattern in women with breast cancer who underwent chemotherapy: strain polar maps analysis 69
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 68
Analytical profile and release of lonidamine from pharmaceutical formulation 68
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 68
The treatment of peritoneal carcinomatosis in elderly patients. 68
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 68
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 67
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 67
Targeted drugs in small-cell lung cancer 67
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation 66
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 66
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 66
One-year follow up assessment of chemotherapy-related vascular toxicity: an arterial stiffness study 66
Applications of genomics in NSCLC 65
Phase II study paclitaxel (PTX) and cisplatin (Cis) in advanced and recurrent head&neck cancer 65
An acute-leukaemia-like picture due to breast carcinoma cells. 65
A randomized factorial trial of sequential doxrubicina and CMF vs CMF and chemoterapy alone vs chemoterapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer 65
Analisi dello stato di metilazione del promoter di O6-methylguanine DNA methyltransferase (MGMT) e TMS1/ASC nei gliomi cerebrali diffusi di basso grado: possibili implicazioni cliniche e prognostiche. 65
INFLUENCE OF CYP2C9 POLYMORPHISM IN LUNG CANCER SUSCEPTIBILITY 64
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 64
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role 64
Left atrial function in patients undergoing chemotherapy: additional value of 2D longitudinal strain 64
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 64
A PHASE III RANDOMIZED TRIAL COMPARING THREE PLATINUM-BASED DOUBLETS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): IMPACT OF PS=2 VS 0 OR 1 AND AGE ³70 VS <70 ON CHEMOTHERAPY OUTCOME 63
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study 63
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 63
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 62
Transpersonal integrated interventions to improve quality of life in cancer patients in all stages of disease 61
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 61
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 61
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 61
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 61
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 61
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 61
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer 61
Espressione differenziale di un panel di miRNA in tumori cerebrali astrogliali con diverso grado di malignità. 61
Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. 60
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 60
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 60
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 59
Sternal metastasis as initial presentation of a unknown rectal cancer 59
Microvessels density evaluation in human meningiomas: an immunohistochemical investigation by the specific marker for neoangiogenesis CD105 (Endoglin). 59
Peritoneal carcinomatosis of colorectal origin. 59
The treatment of recurrent and metastatic cervical carcinoma. Evaluation of an antiblastic combination of methotrexate-adriamycin-bleomycin (MAB) 59
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. 58
Phase II study Paclitaxel (PTX) and Cisplatin (Cis) in advanced and recurrent head and neck cancer 58
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 58
Psycho-Neuro-Endocrine-Immune System (PNEI) Involvement as Prognostic Marker in Breast Cancer Patients at 10 Years of Follow Up 58
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 58
Thyroid function, autoimmunity and nodules in hematological malignancies 58
A PHASE II STUDY (21 day regimen) OF GEMCITABINE (Gem) AND CISPLATIN ( Cis) IN ADVANCED/METASTATIC TRANSITIONAL CELL CARCINOMA (TTC) OF BLADDER 57
[(186)Re]HEDP in the palliation of painful bone metastases from cancers otherthan prostate and breast. 57
Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma. A retrospective study 57
Amplification and overexpression of the PSMB5 gene contribute to Bortezomib resistance in re-treatment of patients with Multiple Myeloma 57
Transpersonal Therapy Combined with Best Supportive Care In Hospice Improve Patient’s Quality of Life and Quality Of Death 56
Analysis of multilayer strain and myocardial work in patients undergoing chemotherapy treatment: a 12 months follow-up 56
Behavior of serum sialic acid levels at various stages of neoplastic disease 55
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer 55
ZD 1839 IRESSA IN HEAVELY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) ASSESSMENT OF TOLERABILITY AND THE CLINICAL BENEFIT 54
First Line Chemotherapy with Oral Vinorelbine (oV) in Elderly Hormone-Refractory Prostate Cancer (HRPC) Patients (pts 54
Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions - Is curative irradiation feasible? Final results of a prospective study 53
Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer 53
null 53
Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy 53
Unusual relapse of hepatocellular carcinoma 53
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 53
PHASE II STUDY PACLITAXEL AND CISPLATIN IN ADVANCED AND RECURRENT HEAD & NECK CANCER 52
From the bench to the bed: individualizing treatment in non-small-cell lungcancer 52
La farmacogenomica nei tumori del polmone 52
Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? 52
Effects of synthetic salmon calcitonin in the treatment of bone lesions of the neoplastic type 52
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 52
Totale 6.863
Categoria #
all - tutte 40.427
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.427


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.754 277 130 10 126 38 238 221 177 34 213 260 30
2020/20211.610 169 18 339 114 186 170 48 148 64 169 118 67
2021/20221.555 10 224 45 40 59 20 84 61 31 244 269 468
2022/20233.927 312 372 174 289 306 401 57 236 1.613 22 96 49
2023/2024998 76 128 66 115 74 261 23 45 3 80 26 101
2024/202540 40 0 0 0 0 0 0 0 0 0 0 0
Totale 11.443